Veloxis Pharmaceuticals is honored to be a sponsor of one of the largest gatherings of transplant recipients in the world: The 2024 Transplant Games of America in Birmingham, AL, on July 5-10! An initiative of the Transplant Life Foundation, the Transplant Games of America raises awareness of the transplant community and honors donors who have given the gift of life. Recipients of organs, eyes, and tissue join living donors, donor families, those on the waiting list, and transplant professionals to celebrate the tremendous impact donations have on the world. Learn more at the Transplant Games of America’s website. #TGA24BHM #Transplant #DonateLife #OrganDonation #TransplantGames
Veloxis Pharmaceuticals, Inc.
Biotechnology Research
Cary, North Carolina 9,659 followers
Let's transform transplant medicine. Together
About us
Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients. Headquartered in Cary, North Carolina, USA, Veloxis is focused on the global development and commercialization of medications utilized by transplant patients and by patients with serious related diseases. We know what transplant means to patients, and we’re leading innovation to improve their experience. For patients, transplant is a life-changing procedure. But changes come with challenges. At Veloxis, our mission is to see and respond to the challenges along the transplant journey. Read our Community Guidelines: https://bit.ly/3FQr7Wg
- Website
-
https://www.veloxis.com
External link for Veloxis Pharmaceuticals, Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Cary, North Carolina
- Type
- Public Company
- Specialties
- Pharmaceuticals, Biotechnology, and Transplant
Locations
-
Primary
Get directions
2000 Regency Pkwy
Suite 500
Cary, North Carolina 27518, US
Employees at Veloxis Pharmaceuticals, Inc.
Updates
-
Did you know that you can give the #GiftOfLife? Every organ donor can save up to 8 lives and enhance over 75 more! Every donation helps—register to become an organ, eye, and tissue donor. #OrganDonation
Register to be an Organ, Eye and Tissue Donor
registerme.org
-
We’re excited to be in the City of Brotherly Love for this year’s American Transplant Congress. Visit us at Booth 613! #ATC2024Philly
-
-
We’re excited about the new clinical data on VEL-101 (also known as FR104) that will be presented at #ATC2024Philly! Three research abstracts will be presented, including one by our very own Simon Tremblay, PharmD, PhD. VEL-101 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients. Read more here: https://bit.ly/vel-101
-
-
Great news! Veloxis is excited to see the Asahi Kasei Healthcare family grow with the announcement of the offer to acquire Calliditas Therapeutics. #AKhealthcare
Today, we announced the acquisition of the Swedish pharmaceuticals company Calliditas Therapeutics for approximately ¥173.9 billion ($1.1 billion at an exchange rate of 1 USD = 157 JPY). The tender offer will begin in July 2024, with the aim of closing by the end of September. “We are confident that the acquisition of Calliditas will further deepen our Global Specialty Pharma into a more highly profitable business model that is distinctly characteristic of Asahi Kasei,” said President Koshiro Kudo at a press conference held today. Calliditas has a strong presence in the U.S. pharmaceuticals market for renal diseases and its product, TARPEYO, is currently the only fully approved product shown to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy who are at risk for disease progression. This acquisition follows that of Veloxis, a US pharmaceutical company which sells an immunosuppressive drug to help prevent organ rejection after kidney transplants, in 2020. “We have been concentrating on expanding the scale of our pharmaceuticals business. The acquisition of Calliditas is the next major element of our strategy,” said Richard A. Packer, Vice-Presidential Executive Officer and Leader of Healthcare sector of Asahi Kasei at the press conference. “We have a strong mix of international executives that will provide a good foundation for Calliditas to continue to grow.” Through these efforts, Asahi Kasei aims to contribute to the fulfilment of unmet medical needs by leveraging synergies with our products and pipeline within the pharmaceutical industry. For more information, visit: https://lnkd.in/eRS6ycSP #Akhealthcare
-
-
Show your appreciation for the nurses supporting the transplant journey! Transplant Nurses Week is April 22-29. Share this post to thank transplant nurses for their care and support. #TransplantNursesWeek
Transplant Nurses Week
itns.org
-
It’s time once again to break out your blue and green clothes. April 12 is Blue and Green Day! Wear your blue and green to help raise awareness of the importance of organ, eye, and tissue donations. #DonateLife
DONATE LIFE BLUE & GREEN DAY SHOW US YOUR DONATE LIFE COLORS!
https://donatelife.net
-
April is National Donate Life Month! This April, think of all the lives that have been saved and families who are together because someone donated. #DonateLife
National Donate Life Month
https://donatelife.net
-
What an incredible evening at last night’s North Carolina Honors Reception! Congratulations to all of the award winners - including our very own Ulf Meier-Kriesche, MD - who took home the 2024 Market Innovation Award. Thanks to the National Kidney Foundation (NKF) Serving the Carolinas for hosting such a wonderful event and for their ongoing work to improve the health and well-being of people affected by kidney disease through prevention, education and empowerment.
-
-
Congratulations are in order for our Chief Scientific Officer Ulf Meier-Kriesche, MD! On March 28th, he will receive the Market Innovation Award at the National Kidney Foundation’s 1st Annual North Carolina Honors Reception in Raleigh. The event will raise funds for the National Kidney Foundation and increase awareness about kidney health and the diagnosis, prevention and treatment of kidney disease. The reception will welcome more than 150 health professionals and advocates in the kidney community to honor extraordinary individuals who have positively impacted the lives of kidney patients across the state. Congratulations, Ulf!
-